Monday, October 26, 2026
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Press releaseGlobeNewswire· April 13, 2026

Pattern to Present at Life Science Innovation Northwest 2026

View original at globenewswire.com
Pattern to Present at Life Science Innovation Northwest 2026 REDMOND, Wash., April 13, 2026 (GLOBE NEWSWIRE) -- Pattern Computer®, Inc…
Opening lines of the source · GlobeNewswire · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • The PDE platform is domain-agnostic and capable of generating transparent, biologically validated insights across all bio-related sectors

    60% confidence
  • Pattern's proprietary mathematical techniques can find complex patterns in very-high-order data that have eluded detection by much larger systems, including LLMs

    60% confidence
  • The PDE provides a new paradigm for science itself, achieving trust and transparency that scientists and industry leaders have been searching for

    60% confidence
  • Pattern is pioneering a fundamentally new approach to ML using proprietary PDE engine, unmatched in ability to reveal previously hidden relationships in complex, high-dimensional data

    60% confidence
  • Pattern's proprietary PDE constitutes a new approach to the scientific method where hypotheses are directly and only derived from data, free of hypothesis-bias

    60% confidence
  • The PDE mathematics is hallucination-free, unlike LLMs, and provides accountability with real-time confidence and risk metrics

    60% confidence
  • Pattern transforms the way correlations and causations are uncovered without bias through pattern discovery

    60% confidence
  • Pattern is setting a new benchmark for transparency and trust in both machine learning and explainable AI by discovering previously unavailable patterns in data

    60% confidence

Cited in these Via News reports

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biotech Catalyst Window: ESMO Data, the Ivonescimab PDUFA and Small-Cap Delistings
Mid-October to November 2026 is a dense catalyst period for clinical-stage biotech. Positive late-stage readouts (ALOFT-IPF, TELIGAN, MIUDELLA, the duvakitug extension) and the ESMO 2026 presentations lead up to the FDA's 14 November PDUFA date for the ivonescimab BLA. At the opposite end of the market, Spago Nanomedical is moving to delist from Nasdaq First North, which shows how hard it is for micro-cap developers to fund themselves. Value is concentrating in companies with late-stage data and near-term regulatory outcomes.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,994
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,994 facts checked against source5,500 source documents archived
Query this data → isubstrate.com